Technology

AriBio on a Roller Coaster Ride… Inventera Inc. Soars, SAM CHUN DANG PHARM CO. LTD Plummets [Bio Market Watch]

KIM SUNG-JIN
2026-11-20 07:02:03
[Edaily Reporter KIM SUNG-JIN ] On the 18th, stock prices in the domestic pharmaceutical and biotech sectors showed a wide divergence depending on individual companies, driven by new drug development achievements and expectations for commercialization. ARIBIOLAB and AriBio Holdings, which had both plummeted nearly 30% the previous day, managed to rebound as the results of the Phase 3 clinical trial for their oral Alzheimer’s disease treatment were reevaluated. SamjinPharmaceutical, AriBio’s second-largest shareholder, also surged after expressing its commitment to commercialization.

Inventera Inc. showed strength on news of preparations for domestic marketing approval of a magnetic resonance imaging (MRI) contrast agent. In contrast, SAM CHUN DANG PHARM CO. LTD’s stock price fell sharply as unforeseen issues arose during the U.S. approval review process for “SCD411,” a biosimilar of the age-related macular degeneration treatment “Eylea.”

ARIBIOLAB and Holdings Rebound Sharply… Success of Phase 3 Trial Re-evaluated
According to KG Zeroin MP Doctor, ARIBIOLAB hit the daily price limit, trading at 5,290 won—up 29.98% from the previous trading day. AriBio Holdings also closed at 3,115 won, up 21.68%. The two stocks, which had plummeted 29.95% and 29.86%, respectively, the previous day, managed to stage a sharp rebound in just one day.
ARIBIOLAB Stock Price Trend (Source: MP Doctor)

The stock prices of AriBio-related companies have been on a rollercoaster ride since the announcement of the results from the global Phase 3 clinical trial of “AR1001,” an oral Alzheimer’s disease treatment candidate currently under development. Following the announcement of the topline results from AR1001’s global Phase 3 clinical trial, “POLARIS-AD,” at the Clinical Trials in Alzheimer’s Disease (CTAD 2026) conference held in Boston on the 17th, the market reaction was so lukewarm that the stock price immediately headed toward the daily price limit down. However, just one day later, on the 18th, the stock hit the daily price limit up, demonstrating a stark contrast in market sentiment.

The reason market expectations were dampened by the topline results is attributed to the somewhat inconsistent therapeutic effects. A key feature of AriBio’s global Phase 3 clinical trial for AR1001 is that the trial was conducted with the patient population divided into two groups. These were the monotherapy group (604 patients), who were not taking existing Alzheimer’s disease treatments, and the overall patient population (1,535 patients), which included those on existing treatments. Participants in the non-monotherapy group were taking existing symptomatic treatments—acetylcholinesterase inhibitors and memantine—at the time of enrollment.

The issue is that while statistical significance was observed in the monotherapy group, the data from the overall patient population did not provide sufficient evidence to claim definitive therapeutic efficacy. In the monotherapy group—which did not take existing Alzheimer’s disease treatments—the rate of deterioration in Clinical Dementia Rating Scale (CDR-SB) scores was approximately 31% lower in the AR1001 treatment group compared to the placebo group. The difference in score change between the two groups was -0.44 points, which was statistically significant (p=0.0266).

In contrast, among the total patient population of 1,535, the difference in score change between the treatment group and the placebo group was only –0.11 points, and it did not reach statistical significance (p=0.4015). This is why, immediately after the clinical results were announced, doubts about the new drug’s efficacy were raised in the market, causing related stocks to plummet.

However, investor sentiment completely reversed the following day. This is believed to be due to the emphasis placed on the fact that the company met the clinical success criteria it had set in advance. In fact, one of the key features of this clinical trial was that it was designed to achieve the primary endpoint even if only one of the two groups—the monotherapy group or the overall patient population—met the criteria. This was agreed upon in advance with regulatory authorities when the clinical trial protocol was submitted.

An expert in the neurotherapeutics development industry stated, “Even if statistical significance was not achieved in the overall patient population, it does not appear to be a major issue,” adding, “If efficacy is clearly demonstrated in the monotherapy group, there is also the option of securing an indication limited to patients who have not taken existing treatments.”

In fact, the significance level set for the monotherapy group was 0.03, and the p-value of 0.0266 confirmed in this study was found to meet that criterion.

The key issue moving forward is whether the FDA will accept the results from the monotherapy group as the basis for approval or require additional clinical trials.

SamjinPharmaceutical Also Surges Over 18%… Reaffirms Commitment to AR1001 Commercialization
SamjinPharmaceutical, the second-largest shareholder of AriBio and holder of the exclusive domestic manufacturing and sales rights for AR1001, also saw its stock price rise significantly. It closed at 20,100 won, up 18.65% from the previous trading day. This marks a strong rebound from the 15.93% plunge the previous day following the announcement of the AR1001 clinical trial results. The rise in SamjinPharmaceutical’s stock price is attributed to the company’s announcement that day that it had successfully evaluated the Phase 3 clinical trial results for AR1001 and would accelerate follow-up development and commercialization.
SamjinPharmaceutical Stock Price Trend (Source: MP Doctor)

SamjinPharmaceutical explained that positive results were confirmed in this Phase 3 clinical trial not only for the primary endpoint in the monotherapy group but also for certain secondary endpoints and biomarkers. In particular, the company stated that a statistically significant difference of 0.7 points was observed in the Mini-Mental State Examination (MMSE) compared to the placebo group, and that p-tau217, a biomarker associated with Alzheimer’s disease, also showed a significant reduction.

The partnership between the two companies dates back to 2022. In May 2022, the two companies signed a memorandum of understanding (MOU) for the joint research and development of treatments for intractable and degenerative diseases. In August of the same year, they formed a “Pharmaceutical and Biotech Technology Management Alliance” and proceeded with mutual equity investments. At that time, SamjinPharmaceutical invested approximately 30 billion won to acquire a stake in AriBio, and AriBio likewise acquired approximately 30 billion won worth of SamjinPharmaceutical stock to establish the partnership.

Collaboration related to AR1001 took place in March 2023, when SamjinPharmaceutical signed an agreement to jointly conduct a domestic Phase 3 clinical trial for AR1001—valued at up to 100 billion won—and to secure exclusive production and sales rights. SamjinPharmaceutical signed a contract under which it paid AriBio an upfront payment of 10 billion won, with an additional 20 billion won to be paid upon fulfillment of certain conditions following the completion of domestic clinical trials, 30 billion won upon new drug approval, and up to 40 billion won based on sales following commercialization.

As of the end of June this year, SamjinPharmaceutical held 1,443,492 shares (5.47%) of AriBio. If AR1001 obtains domestic marketing authorization in the future, SamjinPharmaceutical will be able to handle manufacturing and sales directly, which is expected to generate synergies in terms of both the value of its stake and the commercialization of the drug.

Inventera Inc.
Shares
Soar Amid Preparations for MRI Contrast Agent Approval
Inventera Inc.’s stock price closed at 8,350 won, up 18.95% from the previous trading day. During the session
,
the price rose as high as 8,880 won, with the gain exceeding 26% at one point.
Inventera Inc. Stock Price Trend (Source: MP Doctor)

The rise in the stock price is attributed to news announced the previous day regarding preparations for the approval of “Asolux Injection (INV-002),” a new nano-MRI contrast agent candidate for MR arthrography. On the 17th, Inventera Inc. announced that it had applied to the Ministry of Food and Drug Safety (MFDS) for a pre-NDA (New Drug Application) consultation meeting prior to submitting the marketing authorization application for Asolux Injection. A Pre-NDA meeting is a procedure in which a company discusses clinical, non-clinical, and quality-related submission materials, as well as key issues, with regulatory authorities prior to formally filing a New Drug Application (NDA).

Previously, Inventera Inc. conducted a Phase 3 clinical trial of Asolux Injection involving 85 patients with confirmed or suspected shoulder joint disorders. The trial was conducted at eight leading tertiary hospitals in South Korea, including Seoul National University Bundang Hospital.

AsoLux Injection is distinguished by its use of iron instead of gadolinium, which is primarily used in existing MRI contrast agents. It is being developed specifically for MR arthrography and is designed to be administered directly into the joint cavity without a separate dilution process.

Inventera Inc. obtained the final Clinical Study Report (CSR) for the Phase 3 clinical trial last September and plans to review the data required for a formal marketing authorization application through this pre-submission consultation.

SAM CHUN DANG PHARM CO. LTD
Shares
Approach Daily Lower Limit… FDA Issues Seohan Requesting Additional Information for SCD411 SAM CHUN DANG PHARM CO
. LTD’s stock price fell sharply today. It closed at 137,300 won, down 14.56% from the previous trading day. Early in the session, the price dropped as low as 113,000 won, coming close to
the daily lower limit
of 112,500 won.
SAM CHUN DANG PHARM CO. LTD Stock Price Trend (Source: MP Doctor)

The reason behind this week’s stock decline is believed to be uncertainty surrounding the U.S. approval of “SCD411,” a biosimilar of Eylea, a treatment for age-related macular degeneration. According to SAM CHUN DANG PHARM CO. LTD, the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on August 18 during the SCD411 approval process. A CRL is a Seohan issued by the FDA after reviewing a New Drug Application (NDA) or Biologics License Application (BLA) to notify the applicant that approval cannot be granted based on the currently submitted data and that additional information is required.

In response, SAM CHUN DANG PHARM CO. LTD stated, “There were no significant findings during the FDA inspection, and only one item was requested for clarification in the CRL,” adding, “The company completed the necessary revisions and resubmitted the application to the FDA on November 6.” The company further explained, “In addition to the CRL, the FDA requested documents typically submitted as part of the approval process, such as updates to prescribing information and packaging labels, resubmission of the product name, and updates to safety information,” adding, “The request did not include a requirement for additional clinical trials to demonstrate the product’s equivalence.”

SCD411 is a biosimilar of “Eylea” (active ingredient: aflibercept), a treatment for age-related macular degeneration marketed by global pharmaceutical companies Regeneron and Bayer. Eylea is a treatment that inhibits the formation of abnormal blood vessels within the eye or the leakage of fluid from blood vessels; it is used for conditions such as wet age-related macular degeneration and diabetic macular edema. It works by blocking the action of vascular endothelial growth factor (VEGF) and other factors, and is administered via intravitreal injection. SAM CHUN DANG PHARM CO. LTD has completed the global Phase 3 clinical trial for SCD411 and is pursuing marketing approval in major countries, including the United States.

Economy

Corporation

IT·Science

Economy

From Hanjin to Doosan… Credit Rating Upgrades for BBB-Rated Companies Signal a ‘Positive Trend’

As interest rate hikes increase the burden of corporate financing, attention is focusing on the possibility of credit rating upgrades for BBB-rated companies. With BBB-rated companies such as Hanjin a…
2026-11-19 19:02:04

IT·Science

AriBio on a Roller Coaster Ride… Inventera Inc. Soars, SAM CHUN DANG PHARM CO. LTD Plummets [Bio Market Watch]

On the 18th, stock prices in the domestic pharmaceutical and biotech sectors showed a wide divergence depending on individual companies, driven by new drug development achievements and expectations fo…
2026-11-20 07:02:03